Chapter 1 · Cardiovascular Medicine · Lesson 4
Heart failure and cardiomyopathies
Fellowship-level theory for the RACGP AKT and KFP, built on Australian heart failure guidance, the PBS and current international evidence.
The most recent full Australian heart failure guideline is the 2018 National Heart Foundation/CSANZ guideline.1 It was overtaken in important ways by an Australian consensus statement in the Medical Journal of Australia (2022), which recommends starting all four HFrEF medicine classes early and using SGLT2 inhibitors across the ejection fraction range.2 This lesson teaches the consensus statement and the current PBS, using the ESC classification (HFrEF ≤40%, HFmrEF 41–49%, HFpEF ≥50%).3 Watch for a new Australian guideline.
- 2024: tafamidis (transthyretin amyloid cardiomyopathy) and mavacamten (symptomatic obstructive hypertrophic cardiomyopathy) listed on the PBS from 1 May 2024.8
- Nov 2023: empagliflozin PBS listing for chronic heart failure extended to LVEF above 40%.7 Dapagliflozin is also PBS-listed for heart failure; check the current restriction.
- 2022: Australian consensus statement: four pillars for HFrEF started early; SGLT2 inhibitors for HFmrEF and HFpEF; IV iron for iron deficiency.2
- MBS: natriuretic peptide testing is funded to exclude heart failure in patients outside hospital (item 66829) and in the emergency department (item 66830).9
Each statement below was standard teaching a few years ago. Decide whether it is still true before you tap.
HFrEF means an LVEF below 50%.
Start an ACE inhibitor, titrate it fully, then add a beta-blocker, and consider an MRA months later.
SGLT2 inhibitors are diabetes medicines; nothing improves outcomes in HFpEF.
Treat iron deficiency in heart failure with oral iron.
Cold-start check
Answer these questions before you read the lesson. Getting some wrong is the point: attempting questions before studying helps you remember the answers afterwards, and your score tells you where to spend your time.
1. Under current classification, HFrEF means an LVEF of:
≤40%. HFmrEF is 41–49% and HFpEF ≥50%. The old Australian definition (<50%) is superseded. Read 2.1 Classification by LVEF →
2. In a breathless patient seen in general practice, which NT-proBNP level makes heart failure unlikely?
<125 ng/L (pg/mL) in the non-acute setting. In acute presentations the rule-out level is higher (<300 ng/L). Read 3.2 Natriuretic peptides →
3. Which of these is not one of the four pillars of HFrEF treatment?
Ivabradine. The pillars are ARNI (or ACE inhibitor/ARB), an evidence-based beta-blocker, an MRA and an SGLT2 inhibitor. Ivabradine is an add-on in selected patients. Read 4.1 The four pillars →
4. To prescribe sacubitril/valsartan on the PBS, the patient must:
Stabilised on an ACE inhibitor or ARB first (unless contraindicated or not tolerated), with LVEF ≤40% and NYHA II–IV. Read 4.3 PBS access →
5. Iron deficiency in heart failure is defined as:
Ferritin <100 µg/L, or 100–299 µg/L with transferrin saturation <20%, with or without anaemia. Read 5.2 Iron deficiency →
Your score: / 5
| Score | What to do |
|---|---|
| 5 / 5 | Strong start. Skim the key takeaways, then go straight to the self-check questions. |
| 3–4 / 5 | Read the sections linked from the questions you missed, then do the self-check. |
| 0–2 / 5 | Work through the whole lesson. Your notes are probably based on the 2018 guideline — check the old-notes box above. |
Learning objectives
- Diagnose heart failure in general practice using natriuretic peptides, ECG and echocardiography, and classify it by LVEF.
- Start and titrate the four pillars of HFrEF therapy safely, within PBS rules.
- Manage HFmrEF and HFpEF, iron deficiency, comorbidities and self-management.
- Recognise and manage decompensation, and plan palliative care.
- Recognise the main cardiomyopathies, their red flags and the need for family screening.
How this is examined
- AKT: LVEF categories, NT-proBNP cut-offs, the four pillars, PBS criteria, drugs to avoid, iron thresholds, HCM murmur manoeuvres, amyloid clues, driving.
- KFP: initial investigations for breathlessness, “list the medicines you would start”, monitoring after an MRA, action plans for weight gain, family screening.
- Common trap: using old sequential titration, giving verapamil or an NSAID in HFrEF, prescribing oral iron, or stopping therapy once the LVEF recovers.
Every section carries a GP Institute study-priority rating. It is our editorial judgement, based on the RACGP curriculum, how heavily current Australian guidelines emphasise the topic, patient safety, recent changes, and the themes in published RACGP exam reports. It is not an official RACGP weighting, and any topic can be examined.
| Rating | What it means for your study |
|---|---|
| ★★★★ | Must know. Core, frequently examined, safety-critical or recently changed. Know it cold, without notes. |
| ★★★☆ | High yield. Commonly tested; know the thresholds, drugs and next steps. |
| ★★☆☆ | Know the principles. Understand the reasoning; detailed numbers are less likely to be asked. |
| ★☆☆☆ | Background. Read once for context. |
- 2. Definitions and classification
- 2.1 Classification by LVEF
- 3. Diagnosis in general practice
- 3.2 Natriuretic peptides
- 4. Drug treatment of HFrEF
- 4.1 The four pillars
- 4.2 Starting, titrating and monitoring
- 4.5 Drugs that make heart failure worse
- 5.2 Iron deficiency
- 7.1 Recognising and managing decompensation
- 8.2 Hypertrophic cardiomyopathy
- 10. Old versus new guidance
1. Why it matters ★☆☆☆
Heart failure is one of the commonest reasons older Australians are admitted to hospital, and about half of patients are readmitted within a year of a first admission. It is also one of the conditions in which medicines have changed outcomes most in the last decade: a patient with HFrEF on all four modern drug classes has a substantially lower risk of death and hospitalisation than one on an ACE inhibitor and beta-blocker alone.2,3 Much of that benefit is lost in the community, through delayed diagnosis, under-dosing, therapeutic inertia and avoidable drug harms. These are the GP’s responsibility, and the examiners know it.
Cardiomyopathies are less common but matter for a different reason: they cause heart failure, arrhythmia and sudden death in younger people, often with a genetic basis. The GP finds the index case, recognises the red flags (exertional syncope, a family history of sudden death) and organises screening of relatives.
↔ Swipe sideways to see the whole figure
2. Definitions and classification ★★★★
Heart failure is a clinical syndrome, not a diagnosis in itself: typical symptoms (breathlessness, fatigue, ankle swelling) and signs (raised JVP, crackles, oedema) caused by a structural or functional cardiac abnormality, confirmed by raised natriuretic peptides or objective evidence of congestion. The work-up has three questions: is it heart failure, what is the LVEF, and what is the cause? Treatment depends on all three.
2.1 Classification by LVEF ★★★★
| Category | LVEF | Other criteria | Evidence for prognostic drugs |
|---|---|---|---|
| HFrEF (reduced) | ≤40% | Symptoms ± signs | Strong: four pillars, devices |
| HFmrEF (mildly reduced) | 41–49% | Symptoms ± signs | SGLT2 inhibitor; weaker evidence for the others |
| HFpEF (preserved) | ≥50% | Structural or functional abnormality (LVH, LA enlargement, diastolic dysfunction) and raised natriuretic peptides | SGLT2 inhibitor; comorbidity treatment |
| HF with improved EF | Was ≤40%, now >40% on treatment | — | Continue HFrEF therapy (relapse if withdrawn) |
The 2018 Australian guideline classified any LVEF below 50% as HFrEF.1 The 2022 Australian consensus statement and the PBS use the 40% threshold, so AKT answers should too.2,6
2.2 Severity: NYHA class ★★★☆
| Class | Description | Example |
|---|---|---|
| I | No limitation of ordinary physical activity | Walks briskly up hills without symptoms |
| II | Slight limitation; symptoms with ordinary activity; comfortable at rest | Breathless after two flights of stairs |
| III | Marked limitation; symptoms with less than ordinary activity | Breathless walking across a room or showering |
| IV | Symptoms at rest; any activity increases discomfort | Breathless sitting in a chair |
NYHA class appears in PBS criteria (sacubitril/valsartan requires NYHA II–IV) and in device indications. It changes with treatment, so record it at every review.
2.3 Causes ★★★☆
| Cause | Clues | First tests |
|---|---|---|
| Ischaemic heart disease (commonest in Australia) | Previous MI, angina, risk factors, Q waves | Cardiology referral for coronary assessment |
| Hypertension | Long-standing high BP, LVH | Echo; usually HFpEF |
| Valve disease | Murmur (aortic stenosis, mitral regurgitation) | Echo |
| Arrhythmia | AF with fast ventricular rate (tachycardia-induced cardiomyopathy) | ECG, Holter; reversible with rate or rhythm control |
| Alcohol and drugs | Heavy drinking; methamphetamine, cocaine | History; often reversible with abstinence |
| Cardiotoxic cancer treatment | Anthracyclines, trastuzumab, chest radiotherapy | Echo surveillance with the oncology team |
| Cardiomyopathy (genetic, infiltrative, inflammatory) | Young patient, family history, carpal tunnel, systemic disease | Echo, cardiac MRI, specialist genetic testing (section 8) |
| Rheumatic heart disease | Aboriginal and Torres Strait Islander or migrant background | Echo; RHD register |
| High-output states and others | Thyrotoxicosis, severe anaemia, thiamine deficiency, haemochromatosis | TSH, FBC, iron studies |
3. Diagnosis in general practice ★★★★
3.1 Symptoms and signs ★★★☆
Breathlessness on exertion is the commonest symptom but is non-specific. Orthopnoea, paroxysmal nocturnal dyspnoea, a raised JVP, a third heart sound and a displaced apex beat are more specific. Peripheral oedema and crackles are common but also occur with venous disease, calcium channel blockers, obesity and lung disease. In older people, heart failure may present as fatigue, falls, nocturia, confusion or reduced exercise tolerance attributed to age.
3.2 Natriuretic peptides ★★★★
BNP and NT-proBNP are released from stretched ventricular myocytes. Their main value in general practice is a high negative predictive value: a level below the rule-out threshold makes heart failure unlikely and makes echocardiography less urgent. Medicare funds testing to exclude heart failure in patients presenting outside hospital (item 66829) and in the emergency department (item 66830).9
| Setting | NT-proBNP: HF unlikely | BNP: HF unlikely | Interpretation |
|---|---|---|---|
| Non-acute (general practice) | <125 ng/L | <35 ng/L | Above this: arrange echocardiography |
| Acute (emergency department) | <300 ng/L | <100 ng/L | Higher age-specific cut-offs help rule in |
Thresholds from the ESC guideline (1 ng/L = 1 pg/mL); laboratories may quote their own.3
Higher levels without heart failure
- Older age, female sex
- Atrial fibrillation
- Chronic kidney disease
- Pulmonary embolism, pulmonary hypertension
- ACS, sepsis, severe illness
- Sacubitril/valsartan raises BNP (neprilysin breaks BNP down) but not NT-proBNP
Lower levels despite heart failure
- Obesity (false reassurance is common)
- Flash pulmonary oedema (very early)
- Constrictive pericarditis
- Some HFpEF
- Diuretic treatment already started
To monitor a patient on sacubitril/valsartan, use NT-proBNP, not BNP. In an obese patient with typical symptoms, a “normal” natriuretic peptide does not exclude heart failure; arrange echocardiography if suspicion remains.
3.3 Other investigations ★★★☆
| Test | Why | What to look for |
|---|---|---|
| ECG | A completely normal ECG makes HFrEF unlikely | Q waves, LVH, LBBB (QRS width for CRT), AF, low voltage (amyloid) |
| Echocardiography | Confirms the diagnosis, LVEF and the cause | LVEF, wall thickness, valves, LA size, pulmonary pressure |
| Chest X-ray | Congestion and other causes of breathlessness | Cardiomegaly, upper-lobe diversion, effusions |
| FBC, UEC, eGFR, LFTs | Anaemia, kidney function and baseline potassium before drugs | Hyponatraemia (poor prognosis) |
| Iron studies | Every patient with heart failure | Ferritin and transferrin saturation (section 5.2) |
| TSH, HbA1c, lipids | Causes and comorbidities | Thyroid disease, diabetes |
| Further (specialist) | Cause | Coronary assessment, cardiac MRI, nuclear pyrophosphate scan, genetic tests |
3.4 Diagnostic pathway ★★★☆
4. Drug treatment of HFrEF ★★★★
4.1 The four pillars ★★★★
Four classes each reduce mortality and hospitalisation in HFrEF, and their benefits add together. The 2022 Australian consensus statement recommends that all patients with HFrEF be started on an ARNI (or ACE inhibitor), a beta-blocker, an MRA and an SGLT2 inhibitor. An ARNI or ACE inhibitor is preferred over an ARB.2
| Class | Agents (starting → target dose) | Main cautions | Monitor |
|---|---|---|---|
| ARNI (preferred) or ACE inhibitor | Sacubitril/valsartan 24/26 mg → 97/103 mg twice daily; or ramipril 1.25–2.5 mg → 5 mg twice daily (or 10 mg daily), perindopril, enalapril. ARB (candesartan) if neither tolerated | Hypotension, hyperkalaemia, angioedema history, bilateral renal artery stenosis, pregnancy. 36-hour gap between the last ACE inhibitor dose and the first ARNI dose | BP, potassium, creatinine |
| Beta-blocker (evidence-based only) | Bisoprolol 1.25 → 10 mg daily; carvedilol 3.125 → 25 mg twice daily; metoprolol succinate (CR) 23.75 → 190 mg daily; nebivolol 1.25 → 10 mg daily | Start when euvolaemic; bradycardia, heart block, severe asthma | Heart rate, BP, symptoms |
| MRA | Spironolactone 12.5–25 → 25–50 mg daily; eplerenone 25 → 50 mg daily | Potassium >5.0 mmol/L or eGFR <30 at baseline; gynaecomastia (spironolactone) | Potassium and creatinine closely |
| SGLT2 inhibitor | Dapagliflozin 10 mg or empagliflozin 10 mg daily (no titration) | Genital fungal infection; euglycaemic ketoacidosis (sick-day rules); volume depletion with diuretics; type 1 diabetes | eGFR (an early small fall is expected) |
Doses from Therapeutic Guidelines and AMH; check current product information.4,5 Metoprolol tartrate is not an evidence-based heart failure beta-blocker; use the CR succinate form.
4.2 Starting, titrating and monitoring ★★★★
The older approach of titrating one drug to target before adding the next took many months, and many patients never reached all four. The consensus approach is to start all four at low doses within a few weeks, then titrate each every 2–4 weeks as BP, heart rate, potassium and kidney function allow.2 SGLT2 inhibitors and MRAs barely lower BP, so they can usually be added even when BP limits ARNI or beta-blocker titration.
| Finding | Action |
|---|---|
| Creatinine rise ≤30% (or eGFR fall ≤25%) after starting an ACE inhibitor, ARNI or SGLT2 inhibitor | Expected; continue and recheck |
| Larger rise in creatinine | Review for dehydration, NSAIDs, excess diuretic; reduce the RAAS dose; seek advice if persistent |
| Potassium 5.5–6.0 mmol/L | Halve the MRA (or RAAS) dose; stop potassium supplements and salt substitutes; recheck |
| Potassium >6.0 mmol/L | Stop the MRA; urgent assessment |
| Asymptomatic low BP | Usually no change; review other BP-lowering drugs (e.g. nitrates, alpha-blockers) |
| Symptomatic hypotension | Reduce the diuretic if dry; stagger doses; then reduce RAAS dose |
| Heart rate <50/min or heart block on beta-blocker | Reduce the dose; review other rate-slowing drugs |
Thresholds from the ESC guideline.3 Give sick-day advice: when vomiting, with diarrhoea or unable to eat or drink, temporarily stop the SGLT2 inhibitor, diuretic, ACE inhibitor/ARB/ARNI and MRA (and metformin if taken), and restart within 24–48 hours of eating and drinking normally.
4.3 PBS access ★★★☆
| Medicine | PBS key criteria | Exam point |
|---|---|---|
| Sacubitril/valsartan | Authority (streamlined): NYHA II–IV, LVEF ≤40%, on optimal standard therapy including a beta-blocker, stabilised on an ACE inhibitor or ARB at initiation (unless contraindicated or not tolerated); not with an ACE inhibitor or ARB6 | The guideline prefers an ARNI, but the PBS requires an ACE inhibitor or ARB first |
| Empagliflozin, dapagliflozin | Authority (streamlined) for chronic heart failure; empagliflozin covers LVEF above 40% since November 20237 | Benefit with or without diabetes |
| Eplerenone | Restricted (e.g. after MI with LV dysfunction); spironolactone is unrestricted | Eplerenone for spironolactone-induced gynaecomastia |
| Ivabradine | Authority; sinus rhythm with a raised resting heart rate despite beta-blocker | Not in AF |
| Tafamidis, mavacamten | Specialist-initiated, from 1 May 20248 | ATTR cardiomyopathy; obstructive HCM |
4.4 Other drugs for selected patients ★★☆☆
- Loop diuretics (furosemide): symptom relief for congestion; no mortality benefit. Use the lowest dose that keeps the patient dry; many can reduce or stop once the four pillars are established.
- Ivabradine: sinus rhythm with resting heart rate ≥70/min despite a maximally tolerated beta-blocker, LVEF ≤35%.
- Digoxin: rate control in AF with heart failure; symptom relief in sinus rhythm. Narrow therapeutic range; toxicity with hypokalaemia and kidney impairment.
- Hydralazine plus isosorbide dinitrate: when ACE inhibitors, ARBs and ARNIs are all contraindicated (e.g. severe kidney impairment, angioedema), or in pregnancy.
- Vericiguat: may be considered after recent worsening despite optimal therapy (specialist).2
4.5 Drugs that make heart failure worse ★★★★
- NSAIDs and COX-2 inhibitors: fluid retention, kidney injury, hyperkalaemia with RAAS drugs and MRAs.
- Verapamil and diltiazem in HFrEF: negative inotropes (amlodipine and felodipine are safe).
- Thiazolidinediones (pioglitazone): fluid retention.
- Class I antiarrhythmics (flecainide) and dronedarone in HFrEF or recent decompensation.
- Saxagliptin: increased HF hospitalisation in trials.
- Moxonidine, itraconazole, high-dose corticosteroids, some anticancer drugs; potassium supplements and salt substitutes with an MRA.
- ACE inhibitor + ARB + MRA triple combination: hyperkalaemia and kidney injury.
5. Beyond the four pillars ★★★☆
5.1 Self-management, exercise and vaccination ★★★☆
| Topic | Advice |
|---|---|
| Daily weights | Same scales, each morning after voiding, before breakfast. A gain of more than 2 kg over 2 days, or increasing breathlessness or swelling, triggers the action plan |
| Flexible diuretic plan | Written plan agreed with the GP or HF nurse: e.g. take an extra furosemide dose for 2–3 days and call the clinic |
| Salt and fluid | Avoid high-salt foods; a fluid restriction (about 1.5 L/day) only for congestion or hyponatraemia, not routinely |
| Alcohol | Limit; abstain in alcohol-related cardiomyopathy |
| Exercise | Regular aerobic exercise; refer to a heart failure exercise or cardiac rehabilitation program |
| Medicines | Why each one matters; sick-day rules; no NSAIDs or salt substitutes; check before over-the-counter medicines |
| Vaccination | Annual influenza; pneumococcal, COVID-19 and RSV vaccines as per the Australian Immunisation Handbook19 |
| Mood and sleep | Screen for depression; treat sleep apnoea |
Refer patients after a heart failure admission to a multidisciplinary heart failure disease management program; these programs reduce readmissions and death.1 Use a GP chronic condition management plan to coordinate allied health.
5.2 Iron deficiency ★★★★
Iron deficiency is present in about half of patients with heart failure, often without anaemia. It causes fatigue and poor exercise tolerance independently of haemoglobin. Check ferritin and transferrin saturation in every patient. Because heart failure is an inflammatory state, ferritin is raised, so the thresholds are higher than in the general population.2
| Item | Detail |
|---|---|
| Definition | Ferritin <100 µg/L, or 100–299 µg/L with TSAT <20% |
| Treatment | Intravenous ferric carboxymaltose (or ferric derisomaltose) in symptomatic HFrEF; may be considered in HFmrEF |
| Oral iron | Poorly absorbed in heart failure; did not improve exercise capacity in trials |
| Also | Look for a cause (e.g. GI blood loss on antiplatelets or anticoagulants, coeliac disease) as you would in any patient |
| Monitoring | Phosphate (hypophosphataemia with ferric carboxymaltose); repeat iron studies after about 3 months |
5.3 Devices ★★☆☆
| Device | Usual indication | Benefit |
|---|---|---|
| ICD (primary prevention) | LVEF ≤35% despite at least 3 months of optimal therapy, NYHA II–III, expected survival >1 year (stronger evidence in ischaemic cardiomyopathy) | Prevents sudden arrhythmic death |
| CRT (biventricular pacing) | LVEF ≤35%, sinus rhythm, QRS ≥150 ms with LBBB morphology (also considered 130–149 ms) | Symptoms, hospitalisation and survival |
| Advanced therapies | Persistent NYHA IV or recurrent admissions despite everything | LV assist device, transplant |
Source: ESC guideline.3 Discuss deactivating the ICD’s shock function as part of advance care planning near the end of life.
5.4 Comorbidities ★★★☆
- Atrial fibrillation: anticoagulate according to stroke risk (a NOAC usually); rate control with a beta-blocker, plus digoxin if needed; avoid verapamil and diltiazem in HFrEF. Rhythm control, including catheter ablation, can improve outcomes in selected HFrEF patients.
- Hypertension: treat with heart-failure drugs first; amlodipine if more is needed.
- Diabetes: SGLT2 inhibitor; metformin is safe unless eGFR is low or the patient is unstable; avoid pioglitazone and saxagliptin.
- CKD: do not withhold RAAS drugs or SGLT2 inhibitors because of moderate CKD; adjust and monitor.
- COPD: cardioselective beta-blockers (bisoprolol, metoprolol, nebivolol) are safe.
- Gout: diuretics raise urate; SGLT2 inhibitors lower it; avoid NSAIDs and use colchicine or corticosteroids for flares.
6. HFmrEF and HFpEF ★★★☆
HFpEF is now about half of all heart failure. It is typical of older women with hypertension, obesity, diabetes, AF and CKD. For years no drug improved outcomes; SGLT2 inhibitors changed that, reducing heart failure hospitalisation in large trials across the whole LVEF range. The 2022 Australian consensus recommends that an SGLT2 inhibitor “should be considered” in HFmrEF and HFpEF.2
| Measure | HFmrEF (41–49%) | HFpEF (≥50%) |
|---|---|---|
| SGLT2 inhibitor | Recommended | Recommended |
| Diuretic | For congestion | For congestion |
| ACE inhibitor/ARNI, beta-blocker, MRA | May be considered (weaker evidence) | Not routine for prognosis; use for their own indications (BP, AF rate, post-MI) |
| Sacubitril/valsartan | Not PBS-subsidised (LVEF must be ≤40%) | Not recommended; not PBS-subsidised |
| Comorbidities | Treat | Central to management: BP, AF, obesity, diabetes, sleep apnoea, CKD, anaemia |
| Weight loss | — | In obesity-related HFpEF, semaglutide improved symptoms and exercise capacity (STEP-HFpEF)14 |
| Exercise | Recommended | Recommended |
Before labelling a patient as HFpEF, consider specific causes that need different treatment: cardiac amyloidosis, hypertrophic cardiomyopathy, valve disease (especially aortic stenosis), constrictive pericarditis, and high-output states.
7. Decompensation and palliative care ★★★☆
7.1 Recognising and managing decompensation ★★★★
Most decompensations have a precipitant. Finding it prevents the next one.
| Group | Examples |
|---|---|
| Patient factors | Missed medicines, high salt or fluid intake, alcohol binge |
| Drugs | NSAIDs, corticosteroids, verapamil or diltiazem, pioglitazone, recently stopped diuretics |
| Cardiac | ACS, new AF or other arrhythmia, uncontrolled hypertension, valve deterioration |
| Other illness | Infection (pneumonia, urinary), anaemia, thyroid disease, worsening kidney function, pulmonary embolism |
- Breathlessness at rest, severe orthopnoea, SpO2 <94% (or below the patient’s baseline), respiratory rate >25/min.
- Hypotension (SBP <90 mmHg), cold peripheries, confusion, oliguria (low output).
- Chest pain, syncope, new arrhythmia or heart rate >120 or <40/min.
- Potassium >6.0 mmol/L, sodium <130 mmol/L, or acute kidney injury.
- Failure of the oral diuretic plan, or no one to supervise at home.
A stable patient with mild weight gain and ankle swelling can usually be managed at home: increase the loop diuretic (e.g. double the dose for 2–3 days), check UEC within a few days, weigh daily and review in 2–3 days. Continue the beta-blocker and other prognostic drugs unless the patient is hypotensive or in shock; stopping them increases later risk.
7.2 Advanced heart failure and palliative care ★★☆☆
Heart failure has a worse prognosis than many cancers once a patient has recurrent admissions or NYHA IV symptoms despite therapy. Start advance care planning early, ideally at a stable time: discuss goals, the likely course with sudden death or progressive decline, ICD deactivation, and preferred place of care. Palliative symptom control includes continuing diuretics for breathlessness, low-dose opioids for refractory breathlessness, and management of depression and fatigue. Prognostic medicines that cause side effects can be withdrawn when the focus changes to comfort.
8. Cardiomyopathies ★★★☆
Cardiomyopathies are diseases of the heart muscle not explained by coronary disease, hypertension, valve disease or congenital disease. The ESC 2023 classification uses the dominant phenotype: dilated, hypertrophic, restrictive, arrhythmogenic right ventricular and non-dilated left ventricular cardiomyopathy.11 Many are genetic, so the family history (three generations, including sudden unexplained deaths under 40) is part of every assessment.
8.1 Dilated cardiomyopathy ★★★☆
A dilated, poorly contracting left ventricle without enough coronary disease or loading conditions to explain it. Causes include genetic variants (in up to a third), alcohol, myocarditis, cancer treatment, tachycardia, peripartum cardiomyopathy and endocrine disease. Treatment is standard HFrEF therapy plus treatment of the cause. Alcohol-related and tachycardia-induced cardiomyopathy often recover substantially.
When the LVEF recovers on treatment, do not stop the heart failure medicines. In the TRED-HF trial, about 40% of patients with recovered dilated cardiomyopathy relapsed within 6 months of phased withdrawal.13
8.2 Hypertrophic cardiomyopathy ★★★★
HCM is unexplained LV hypertrophy (wall thickness ≥15 mm in adults, or ≥13 mm in a relative of a patient), usually autosomal dominant (sarcomere gene variants). Around two-thirds of patients have dynamic LV outflow tract obstruction at rest or on provocation. It is an important cause of sudden cardiac death in young people.11
| Area | Key points |
|---|---|
| Presentation | Often asymptomatic (murmur, abnormal ECG, family screening); exertional breathlessness, chest pain, palpitations, exertional syncope (red flag), sudden death |
| Murmur | Ejection systolic murmur at the left sternal edge that increases with Valsalva and standing (less preload) and decreases with squatting and handgrip; opposite to aortic stenosis |
| ECG | Abnormal in most: LVH, deep T-wave inversion, Q waves |
| Diagnosis | Echocardiography, cardiac MRI; specialist genetic testing |
| Treatment (specialist) | Beta-blocker, then verapamil or diltiazem; disopyramide; mavacamten for symptomatic obstructive HCM (PBS); septal myectomy or alcohol septal ablation; ICD if high sudden-death risk |
| Avoid with obstruction | Dehydration, vasodilators (nitrates, dihydropyridines), PDE5 inhibitors, high-dose diuretics, digoxin |
| Sport | Individualised specialist advice; avoid until assessed |
| Family | Screen first-degree relatives (section 8.5) |
8.3 Restrictive cardiomyopathy and cardiac amyloidosis ★★★☆
A stiff, non-dilated ventricle with preserved or mildly reduced LVEF, large atria and prominent right-sided signs. Cardiac amyloidosis is the cause GPs are most likely to meet and miss. Wild-type transthyretin (ATTR) amyloidosis affects older men in particular; it is an under-recognised cause of HFpEF.12
| Domain | Clue |
|---|---|
| History | Bilateral carpal tunnel syndrome, lumbar spinal stenosis, biceps tendon rupture (often years earlier); intolerance of antihypertensives; peripheral or autonomic neuropathy |
| ECG and echo mismatch | Low or normal QRS voltage despite thick LV walls; pseudo-infarct Q waves; conduction disease, AF |
| Blood tests | Persistently raised troponin; NT-proBNP out of proportion; proteinuria (AL amyloid) |
| Echo | LV wall ≥12 mm, apical sparing of strain, biatrial enlargement |
Diagnosis: first exclude AL (light-chain) amyloidosis with serum free light chains and serum and urine immunofixation, because AL amyloid is a haematological emergency. If there is no monoclonal protein, a technetium pyrophosphate (bone) scan with grade 2–3 cardiac uptake is diagnostic of ATTR amyloidosis without biopsy; genetic testing then separates wild-type from hereditary disease.12 Tafamidis is PBS-listed for ATTR cardiomyopathy (specialist).8 Other restrictive causes include haemochromatosis, sarcoidosis, radiation and endomyocardial fibrosis.
8.4 Takotsubo, myocarditis and peripartum cardiomyopathy ★★☆☆
| Condition | Features | GP points |
|---|---|---|
| Takotsubo syndrome | Postmenopausal women; emotional or physical trigger; mimics ACS; apical ballooning; coronary arteries without culprit lesion | Manage as ACS until proven otherwise; LV function usually recovers within weeks; recurrence possible |
| Myocarditis | Younger; viral illness, some medicines (e.g. clozapine), mRNA vaccines (rare); chest pain, troponin rise, arrhythmia | Cardiac MRI; no strenuous or competitive exercise initially (about 1 month), then an individualised return (2025 ESC; see Lesson 5); clozapine monitoring |
| Peripartum cardiomyopathy | LVEF <45% in the last month of pregnancy or months after delivery, no other cause | Consider in any breathless postpartum woman (NT-proBNP, echo). ACE inhibitors, ARNI, MRA and SGLT2 inhibitors are contraindicated in pregnancy (ACE inhibitors such as enalapril can be used when breastfeeding); specialist advice on future pregnancy and contraception |
| Cancer-therapy related | Anthracyclines (dose-related, may be late), trastuzumab (often reversible) | Echo surveillance; long-term follow-up of childhood cancer survivors |
8.5 Family screening ★★★☆
9. Special groups and driving ★★☆☆
9.1 Special groups ★★☆☆
- Aboriginal and Torres Strait Islander people: heart failure occurs earlier and more often; rheumatic heart disease is a key cause. Check the RHD register and secondary prophylaxis, work with Aboriginal health practitioners, and use culturally safe heart failure programs.18
- Older people and frailty: titrate more slowly; review falls, postural hypotension, polypharmacy and cognition; set goals with the patient.
- Pregnancy: stop ACE inhibitors, ARBs, ARNI, MRAs and SGLT2 inhibitors before conception where possible; specialist pre-pregnancy counselling for any woman with cardiomyopathy.
- Rural and remote: telehealth heart failure nurse programs; plan pathology monitoring in advance.
9.2 Driving ★★★☆
| Condition | Private | Commercial |
|---|---|---|
| Heart failure | Not fit if symptoms on moderate exertion; conditional licence possible with good treatment response and minimal symptoms | No unconditional licence. Conditional licence needs LVEF ≥40% and exercise tolerance ≥90% of predicted, with annual review |
| HCM | Conditional licence if minimal symptoms and no arrhythmia or syncope | Conditional licence needs LVEF ≥40% and no syncope, severe LVH, family history of sudden death or ventricular arrhythmia on Holter |
| ICD (primary prevention) | Conditional licence possible 2 weeks after implantation | Not for at least 6 months; then conditional if no shocks and LVEF ≥40% |
| Pacemaker (including CRT) | At least 2 weeks | At least 4 weeks |
Source: Austroads, Assessing Fitness to Drive.10
10. Old versus new guidance ★★★★
| Topic | Old teaching | Current |
|---|---|---|
| HFrEF definition | LVEF <50% (2018 Australian guideline) | LVEF ≤40%; HFmrEF 41–49%; HFpEF ≥50% |
| Starting therapy | Sequential: ACE inhibitor to target, then beta-blocker, then MRA | All four pillars started early, then titrated |
| First-line RAAS drug | ACE inhibitor | ARNI preferred (PBS still needs an ACE inhibitor or ARB first) |
| SGLT2 inhibitors | Diabetes drugs | Heart failure pillar at any LVEF, with or without diabetes |
| HFpEF | No disease-modifying therapy | SGLT2 inhibitor; treat comorbidities; look for amyloid |
| Iron deficiency | Oral iron if anaemic | IV iron if ferritin <100, or 100–299 with TSAT <20% |
| Recovered LVEF | Consider stopping therapy | Continue (relapse risk) |
| ATTR amyloid, obstructive HCM | Supportive care only | Tafamidis and mavacamten (PBS, specialist) |
From the RACGP public exam reports15,16
- Topic coverage: the AKT 2026.2 report lists congestive cardiac failure management among the cardiovascular topics examined. The published reports do not comment on specific heart failure errors.
- Answer technique (KFP 2025.1): give only the number of answers requested, be specific (“spironolactone 12.5 mg daily”, not “diuretic”), and use all the information in the scenario.
Other common traps
- Choosing sacubitril/valsartan as the very first RAAS drug on the PBS, or starting it the day after the last ACE inhibitor dose.
- Starting an MRA when potassium is above 5.0 mmol/L, or adding potassium supplements.
- Prescribing oral iron, or deciding a ferritin of 150 µg/L excludes iron deficiency.
- Using verapamil, diltiazem or an NSAID in HFrEF.
- Stopping the beta-blocker during mild decompensation.
11. Worked case (KFP style)
Peter Collins, aged 68 years, has 3 months of increasing breathlessness on exertion and ankle swelling. He had an inferior MI 6 years ago. He takes aspirin, atorvastatin and amlodipine 10 mg. Pulse 92 regular, BP 132/84 mmHg, JVP raised 4 cm, bibasal crackles, pitting oedema to mid-shin. BMI 29. ECG: sinus rhythm, inferior Q waves, QRS 110 ms.
Question 1. List up to four investigations you would arrange now.
Show answer
- Transthoracic echocardiogram.
- NT-proBNP (or BNP).
- UEC with eGFR and potassium (also LFTs).
- FBC and iron studies (ferritin, transferrin saturation).
Also accepted: chest X-ray, TSH, HbA1c. Scores zero: stress test, D-dimer, troponin without chest pain, “bloods” (not specific).
Echo shows LVEF 30% with inferior akinesis. NT-proBNP is 2,400 ng/L. Potassium 4.6 mmol/L, eGFR 62 mL/min/1.73 m2. Ferritin 80 µg/L, TSAT 14%, Hb 132 g/L.
Question 2. List up to five changes to his medicines over the next 2–4 weeks.
Show answer
- Start furosemide (e.g. 40 mg daily) for congestion.
- Start an ACE inhibitor at low dose (e.g. ramipril 2.5 mg daily), planning a switch to sacubitril/valsartan.
- Start dapagliflozin or empagliflozin 10 mg daily.
- Start spironolactone 12.5–25 mg daily.
- Start bisoprolol 1.25 mg daily (or another evidence-based beta-blocker) once euvolaemic.
Stopping amlodipine to make room for the prognostic drugs is also reasonable. Scores zero: verapamil, digoxin as a first step, oral iron, starting sacubitril/valsartan first (not PBS-eligible), metoprolol tartrate.
Question 3. What is the most appropriate treatment for his iron studies? Write one answer.
Show answer
- Intravenous ferric carboxymaltose (or ferric derisomaltose).
Ferritin <100 µg/L defines iron deficiency in heart failure regardless of haemoglobin. Also arrange appropriate assessment for GI blood loss (he takes aspirin). Scores zero: oral iron, “no treatment as not anaemic”.
Three months later he is on sacubitril/valsartan 49/51 mg twice daily, bisoprolol 5 mg, spironolactone 25 mg and dapagliflozin. He is NYHA II. Repeat echo: LVEF 32%. ECG QRS 112 ms.
Question 4. What is the most appropriate next step regarding device therapy? Write one answer.
Show answer
- Refer to cardiology for assessment for a primary prevention ICD.
LVEF ≤35% after 3 months of optimal therapy, NYHA II, ischaemic cause. CRT is not indicated with a QRS of 112 ms. Scores zero: CRT, pacemaker, “no further action”.
12. Self-check questions
These questions are written at or above AKT difficulty. Every option is plausible and the options are deliberately similar. Commit to an answer before revealing the explanation.
Margaret Lee, aged 72 years, has had 2 months of breathlessness walking up hills. She has hypertension treated with perindopril. She has no orthopnoea or ankle swelling. Pulse 72 regular, BP 134/80 mmHg, JVP not raised, chest clear, no oedema. BMI 24. ECG normal. Results today:
| Test | Result | Normal range |
|---|---|---|
| NT-proBNP | 90 ng/L | See lab comment: <125 ng/L makes HF unlikely |
| Haemoglobin | 134 g/L | 115–165 |
| eGFR | 78 mL/min/1.73 m2 | >60 |
What is the MOST appropriate next step?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: B. Look for a non-cardiac cause of her breathlessness
Feedback: This question requires candidates to use the negative predictive value of natriuretic peptides. In a non-acute setting, NT-proBNP below 125 ng/L makes heart failure unlikely. She is not obese (which can falsely lower levels), has a normal ECG and no signs of congestion, so the next step is to look for another cause (lung disease, deconditioning, anaemia excluded, thyroid, etc.).
- Arrange transthoracic echocardiography this week: indicated if NT-proBNP is ≥125 ng/L or the ECG is abnormal; neither applies.
- Refer for cardiac MRI to assess for HFpEF: HFpEF also requires raised natriuretic peptides; MRI is not a first-line test.
- Repeat NT-proBNP in 3 months to confirm the result: a single low result in a non-obese patient is reliable; repeating delays the real diagnosis.
- Start furosemide 20 mg daily and review in 1 week: no evidence of congestion; empirical diuretics cause harm.
Reference: ESC heart failure guideline 2021; NHFA/CSANZ heart failure guideline 2018.
Arthur Banks, aged 70 years, has ischaemic HFrEF (LVEF 30%), NYHA II. He takes perindopril 5 mg, bisoprolol 5 mg and furosemide 40 mg daily, and is euvolaemic. He does not have diabetes. Pulse 64 regular, BP 118/72 mmHg. Results today:
| Test | Result | Normal range |
|---|---|---|
| Potassium | 5.3 mmol/L* | 3.5–5.2 |
| eGFR | 46 mL/min/1.73 m2* | >60 |
| Sodium | 138 mmol/L | 135–145 |
Which addition to his treatment is MOST appropriate now?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: A. Add dapagliflozin 10 mg once daily
Feedback: This question requires candidates to add a missing pillar while respecting a potassium constraint. He lacks an MRA and an SGLT2 inhibitor. With potassium 5.3 mmol/L (above 5.0), an MRA should not be started now. An SGLT2 inhibitor reduces death and hospitalisation, works without diabetes, is safe at this eGFR, barely lowers BP and tends to lower potassium.
- Add digoxin 62.5 micrograms daily: no AF and no mortality benefit; not before the four pillars.
- Add eplerenone 25 mg once daily: MRA initiation is avoided when potassium is above 5.0 mmol/L.
- Add ivabradine 5 mg twice daily: needs a resting heart rate of at least 70/min in sinus rhythm; his is 64.
- Add spironolactone 25 mg once daily: same potassium problem; also a higher starting dose than advised with eGFR 46.
Reference: Sindone AP, et al. MJA 2022 consensus statement; Therapeutic Guidelines: Cardiovascular.
Helen Fraser, aged 64 years, has HFrEF (LVEF 32%), NYHA II. She has been stable for 3 months on ramipril 5 mg twice daily, carvedilol 25 mg twice daily, spironolactone 25 mg and empagliflozin 10 mg daily. BP 124/78 mmHg, potassium 4.7 mmol/L, eGFR 70 mL/min/1.73 m2. She meets the PBS criteria and you plan to switch her to sacubitril/valsartan.
What is the MOST appropriate way to make the switch?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: A. Start it 36 hours after the last ramipril dose
Feedback: This question requires candidates to know the ACE inhibitor–ARNI washout. Neprilysin inhibition plus ACE inhibition greatly increases the risk of angioedema (both pathways break down bradykinin), so at least 36 hours must pass between the last ACE inhibitor dose and the first sacubitril/valsartan dose.
- Start it now and halve the ramipril dose: co-administration is contraindicated at any dose.
- Start it the morning after the last ramipril dose: usually less than 36 hours.
- Start it with ramipril, then stop ramipril in 1 week: a week of overlap: high angioedema risk.
- Stop ramipril and start it 7 days later: safe but leaves a week without RAAS blockade; unnecessary.
Reference: Australian Medicines Handbook; sacubitril/valsartan product information.
Raymond Ng, aged 69 years, has HFrEF (LVEF 34%) and remains NYHA II–III despite optimised doses of the four pillars. He reports fatigue. A colonoscopy last year was normal and coeliac serology is negative. Results today:
| Test | Result | Normal range |
|---|---|---|
| Haemoglobin | 128 g/L | 130–180 |
| Ferritin | 180 µg/L | 30–500 |
| Transferrin saturation | 15%* | 20–50 |
What is the MOST appropriate management?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: B. Organise intravenous ferric carboxymaltose
Feedback: This question requires candidates to apply the heart-failure-specific definition of iron deficiency. A ferritin of 100–299 µg/L with TSAT below 20% is iron deficiency in heart failure. He is symptomatic despite optimal therapy, so IV iron is recommended to improve symptoms, exercise capacity and quality of life.
- No treatment as ferritin is above 100: ignores the TSAT criterion; ferritin is raised by inflammation in heart failure.
- Recheck iron studies and Hb in 3 months: delays treatment of a confirmed, treatable cause of symptoms.
- Refer for gastroscopy and colonoscopy first: GI causes have been reasonably excluded (recent normal colonoscopy, negative coeliac serology) and do not need to delay treatment.
- Start oral ferrous sulfate 325 mg daily: oral iron did not improve exercise capacity in HFrEF.
Reference: Sindone AP, et al. MJA 2022 consensus statement.
Douglas White, aged 79 years, has had 18 months of exertional breathlessness and ankle swelling. Over the past year his amlodipine and perindopril were stopped because of dizziness. He had bilateral carpal tunnel release 8 years ago and has lumbar spinal stenosis. ECG: sinus rhythm with low QRS voltages in the limb leads*. Echo: LV wall thickness 16 mm, LVEF 52%, biatrial enlargement, apical sparing of longitudinal strain. NT-proBNP 3,800 ng/L; hs-troponin T persistently 45–50 ng/L (normal <15). Serum free light chain ratio and serum and urine immunofixation are normal. A technetium pyrophosphate scan shows grade 3 cardiac uptake.
What is the MOST likely diagnosis?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: H. Wild-type ATTR amyloidosis
Feedback: This question requires candidates to recognise cardiac amyloidosis from its red flags and to apply the non-biopsy diagnostic rule. Bilateral carpal tunnel syndrome, spinal stenosis, intolerance of antihypertensives, low voltages despite thick walls, apical sparing and persistently raised troponin point to amyloid. Grade 2–3 pyrophosphate uptake with no monoclonal protein is diagnostic of ATTR. In an older man, wild-type is the most likely form (genetic testing confirms).
- AL (light-chain) amyloidosis: excluded by a normal free light chain ratio and immunofixation.
- Anderson–Fabry disease: usually younger, with neuropathic pain, angiokeratomas, proteinuria; LVH with high, not low, voltages.
- Cardiac haemochromatosis: iron overload causes dilated or restrictive disease, not pyrophosphate uptake.
- Cardiac sarcoidosis: conduction disease and patchy scar in younger patients; not pyrophosphate positive.
- Constrictive pericarditis: normal wall thickness, pericardial thickening; no myocardial tracer uptake.
- Hypertensive heart disease: LVH with high voltages; his BP is low enough that antihypertensives were stopped.
- Hypertrophic cardiomyopathy: LVH usually with high voltages; no pyrophosphate uptake; younger onset.
Reference: Garcia-Pavia P, et al. ESC position statement on cardiac amyloidosis 2021.
Jacob Turner, aged 17 years, comes in because his 22-year-old sister has just been diagnosed with hypertrophic cardiomyopathy. Her cardiac genetics clinic found a pathogenic MYBPC3 variant and has written to suggest family testing. Jacob plays representative football, has no symptoms, and his examination is normal.
What is the MOST appropriate screening for Jacob?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: C. Genetic test for the family variant, plus ECG and echo
Feedback: This question requires candidates to apply cascade screening when a familial variant is known. First-degree relatives should be offered predictive (cascade) testing for the specific variant after genetic counselling, together with clinical screening (ECG and echocardiogram). A variant-negative relative can usually be discharged from follow-up; a variant-positive one needs regular review. He plays competitive sport, so screening is urgent.
- Echocardiogram and ECG only, repeated every 5 years: misses the chance of definitive genetic answers, and adolescents need screening every 1–3 years if not genotyped.
- Exercise stress test, then echo if it is abnormal: not a screening test for HCM.
- No testing unless he develops exertional symptoms: sudden death can be the first symptom.
- Whole-genome sequencing before any cardiac testing: unnecessary when the family variant is known, and it should not delay clinical screening.
Reference: ESC cardiomyopathy guideline 2023.
Stephen Rowe, aged 58 years, was diagnosed with dilated cardiomyopathy 18 months ago (LVEF 28%; no coronary disease; alcohol intake was 2 standard drinks a week). On sacubitril/valsartan 97/103 mg twice daily, bisoprolol 10 mg, spironolactone 25 mg and empagliflozin 10 mg, he is now NYHA I and his LVEF is 55%. He feels well and asks whether he can stop some of his medicines.
What is the MOST appropriate management?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: E. Unchanged: continue all four at current doses
Feedback: This question requires candidates to manage heart failure with improved ejection fraction. Recovery of LVEF on treatment reflects remission, not cure. In the TRED-HF trial, about 40% of patients with recovered dilated cardiomyopathy relapsed within 6 months when therapy was withdrawn, so guideline therapy is continued indefinitely.
- Stop empagliflozin and continue the other three: SGLT2 inhibitors reduce events across all LVEF ranges.
- Stop spironolactone and continue the other three: no evidence supports selective withdrawal; he has no side effects.
- Switch sacubitril/valsartan to low-dose ramipril: a step down in proven therapy without reason.
- Taper all four medicines over the next 6 months: the strategy that caused relapse in TRED-HF.
Reference: Halliday BP, et al. TRED-HF. Lancet 2019.
Kevin Doyle, aged 76 years, has HFrEF (LVEF 35%) on sacubitril/valsartan, bisoprolol, spironolactone, dapagliflozin and furosemide 40 mg daily. He phones because his weight has risen 3 kg over 3 days after a weekend of salty takeaway food. He is a little more breathless climbing stairs and his ankles are puffier. He sees you that afternoon: pulse 78 regular, BP 128/76 mmHg, SpO2 96%, respiratory rate 16, mild basal crackles, oedema to mid-shin. Potassium 4.6 mmol/L, eGFR 58 mL/min/1.73 m2 (his baseline). He lives with his wife, who helps with his medicines.
What is the MOST appropriate next step?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: C. Double his furosemide dose and review in 2 days
Feedback: This question requires candidates to manage mild decompensation safely at home. He has a clear precipitant (salt), no red flags (normal saturation and respiratory rate, stable BP and kidney function), and good support. Increasing the loop diuretic, daily weights, salt advice, UEC within a few days and early review is appropriate.
- Add hydrochlorothiazide 25 mg daily to furosemide: sequential nephron blockade is for diuretic resistance, with close monitoring; not the first step.
- Admit to hospital for intravenous furosemide: no features of severe decompensation; oral escalation is appropriate first.
- Restrict fluids to 1 litre a day and review in a week: too restrictive, and a week is too long to review a decompensating patient.
- Stop bisoprolol until his weight returns to baseline: beta-blockers should be continued in mild decompensation; stopping them increases later risk.
Reference: NHFA/CSANZ heart failure guideline 2018; ESC heart failure guideline 2021.
Got this wrong? Re-read 7.1 Recognising and managing decompensation →
Darren Price, aged 52 years, drives a semi-trailer for a living. He has ischaemic HFrEF diagnosed 6 months ago and is now on optimised therapy, NYHA I. His latest echocardiogram shows an LVEF of 35%. He has no arrhythmia and has not had an ICD. He asks whether he can keep driving trucks.
What is the MOST appropriate advice about commercial driving?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: E. Not fit to drive commercially while LVEF is below 40%
Feedback: This question requires candidates to apply the Austroads commercial standard for heart failure. A commercial driver with heart failure cannot hold an unconditional licence; a conditional licence requires an LVEF of at least 40% and exercise tolerance of at least 90% of predicted, with annual review. His LVEF is 35%, so he does not meet the standard regardless of symptoms. He may still meet the private standard.
- Fit to drive commercially after a 4-week stand-down: the commercial non-driving period after AMI or PCI, not a heart failure rule.
- Fit to drive commercially if NYHA class I or II: symptom class does not override the LVEF requirement.
- Fit to drive commercially once an ICD is implanted: commercial drivers cannot drive for at least 6 months after an ICD, and still need LVEF ≥40%.
- Fit to drive commercially with annual cardiology review: annual review is a condition, but only once LVEF and exercise criteria are met.
Reference: Austroads, Assessing Fitness to Drive (cardiovascular conditions).
Gloria Santos, aged 74 years, has heart failure with LVEF 58%, LV hypertrophy and a raised NT-proBNP. She has type 2 diabetes (HbA1c 7.4%) on metformin, hypertension on perindopril and amlodipine (BP 128/76 mmHg), and BMI 36. She takes furosemide 20 mg daily and is euvolaemic but remains NYHA II. eGFR 55 mL/min/1.73 m2, potassium 4.4 mmol/L. Pyrophosphate scan was negative.
Which addition is MOST appropriate to reduce her risk of heart failure hospitalisation?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: C. Empagliflozin 10 mg once daily
Feedback: This question requires candidates to choose the one drug class with strong outcome evidence in HFpEF. SGLT2 inhibitors reduce heart failure hospitalisation in HFpEF, with or without diabetes, and are PBS-listed for heart failure with LVEF above 40%. It also helps her diabetes and weight. Amyloid has been excluded.
- Bisoprolol 2.5 mg once daily: no prognostic benefit in HFpEF without another indication (AF, angina, post-MI).
- Digoxin 62.5 micrograms once daily: no role in HFpEF in sinus rhythm.
- Sacubitril/valsartan 24/26 mg bd: not recommended in HFpEF and not PBS-subsidised for LVEF above 40%; she already has a RAAS drug.
- Spironolactone 25 mg once daily: weaker evidence (may be considered in selected patients), and not the first addition.
Reference: Sindone AP, et al. MJA 2022 consensus statement; PBS Schedule.
Self-check score: / 10
Sure but wrong:
Any “sure but wrong” answer is your highest exam risk. Re-read those sections first, then use the flashcards at the end of the lesson. Your selections are not saved; the score resets when you leave the page.
Tick each one you can do without notes. Anything left unticked is your revision list.
- Not yet? Re-read section 2.1 →
- Not yet? Re-read section 3.2 →
- Not yet? Re-read section 4.1 →
- Not yet? Re-read section 4.2 →
- Not yet? Re-read section 4.3 →
- Not yet? Re-read section 4.5 →
- Not yet? Re-read section 5.2 →
- Not yet? Re-read section 8.3 →
Ready on of 8.
13. Key takeaways
- Classification: HFrEF ≤40%, HFmrEF 41–49%, HFpEF ≥50%; improved EF keeps HFrEF therapy.
- Natriuretic peptides: NT-proBNP <125 ng/L (non-acute) or <300 ng/L (acute) makes HF unlikely; obesity lowers levels; sacubitril/valsartan raises BNP but not NT-proBNP.
- Four pillars for HFrEF: ARNI (or ACE inhibitor/ARB), evidence-based beta-blocker, MRA, SGLT2 inhibitor; start all within weeks, then titrate.
- PBS ARNI: LVEF ≤40%, NYHA II–IV, stabilised on ACE inhibitor/ARB first; wait 36 hours after the last ACE inhibitor dose.
- Monitoring: creatinine rise up to 30% is acceptable; MRA not started if K+ >5.0; halve at 5.5–6.0; stop above 6.0.
- Avoid: NSAIDs, verapamil/diltiazem (HFrEF), pioglitazone, saxagliptin, flecainide, ACE inhibitor + ARB + MRA.
- Iron: ferritin <100, or 100–299 with TSAT <20%: IV ferric carboxymaltose, not oral iron.
- HFpEF: SGLT2 inhibitor, diuretic for congestion, treat comorbidities, exclude amyloid and HCM.
- Devices: LVEF ≤35% after 3 months of optimal therapy: ICD; plus QRS ≥150 ms with LBBB: CRT.
- Decompensation: >2 kg in 2 days triggers the action plan; continue beta-blockers; hospital if red flags.
- HCM murmur: louder with Valsalva and standing, softer with squatting; exertional syncope is a red flag; screen first-degree relatives.
- Amyloid: bilateral carpal tunnel, low voltage with thick walls, exclude AL first, then pyrophosphate scan; tafamidis on the PBS.
Your revision plan
| When | What to do |
|---|---|
| Today | Finish the lesson, both question sets and the readiness checklist. Note every “sure but wrong” answer. |
| Day 3 | Do this lesson’s 10 flashcards again (end of this lesson). Re-read every section you marked “Not yet”. |
| Day 7 | Redo the self-check questions without looking at the lesson. Aim for 8/10 with no “sure but wrong”. |
| Day 21 | Do the cardiovascular chapter flashcard deck, then one timed block of mixed questions at exam pace. |
| Week before the exam | Re-read the key takeaways, Table 18 and the old-notes box. Do the chapter flashcard deck once more. |
Your next step
Use your scores from the cold-start check and the self-check questions to choose your next step.
Flashcards: 10 high-yield recall cards
Finish the lesson by testing your recall. Say the answer out loud before you tap the card to flip it, then mark “I knew this” only if you were fully right without looking. Repeat the cards on day 3 and day 21, and use the cardiovascular chapter deck for later reviews.
14. References and recommended reading
References
- Atherton JJ, Sindone A, De Pasquale CG, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: guidelines for the prevention, detection, and management of heart failure in Australia 2018. Heart Lung Circ 2018;27:1123–208. heartlungcirc.org (accessed 10 Nov 2026).
- Sindone AP, De Pasquale C, Amerena J, et al. Consensus statement on the current pharmacological prevention and management of heart failure. Med J Aust 2022;217(4):212–7. mja.com.au (accessed 10 Nov 2026).
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–726; and 2023 focused update. Eur Heart J 2023;44:3627–39.
- Therapeutic Guidelines. Cardiovascular (current version): heart failure. Melbourne: Therapeutic Guidelines Limited. tg.org.au (accessed 10 Nov 2026).
- Australian Medicines Handbook. Adelaide: AMH Pty Ltd (current edition): heart failure drugs. amhonline.amh.net.au (accessed 10 Nov 2026).
- Pharmaceutical Benefits Advisory Committee. Sacubitril with valsartan: public summary document, November 2024 (current restriction criteria). pbs.gov.au (accessed 10 Nov 2026).
- newsGP. Expanded PBS eligibility for heart failure and migraine medicines. RACGP; 2023. racgp.org.au (accessed 10 Nov 2026).
- Minister for Health and Aged Care. Government adds two new heart disease treatments on the PBS (tafamidis, mavacamten; 1 May 2024). health.gov.au (accessed 10 Nov 2026).
- Medical Services Advisory Committee. Application 1826: NT-proBNP testing to support management of patients with heart failure (describes current MBS items 66829 and 66830). 2026. msac.gov.au (accessed 10 Nov 2026).
- Austroads. Assessing Fitness to Drive for commercial and private vehicle drivers. Part B, section 2: Cardiovascular conditions. austroads.gov.au (accessed 10 Nov 2026).
- Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J 2023;44:3503–626.
- Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2021;42:1554–68.
- Halliday BP, Wassall R, Lota AS, et al (TRED-HF). Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy. Lancet 2019;393:61–73.
- Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al (STEP-HFpEF). Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389:1069–84.
- The Royal Australian College of General Practitioners. KFP 2025.1 public exam report. Melbourne: RACGP; 2025. racgp.org.au (accessed 10 Nov 2026).
- The Royal Australian College of General Practitioners. AKT 2026.2 public exam report. Melbourne: RACGP; 2026. racgp.org.au (accessed 10 Nov 2026).
- The Royal Australian College of General Practitioners. AKT and KFP: general exam delivery information. racgp.org.au (accessed 10 Nov 2026).
- RHDAustralia (ARF/RHD writing group). The 2025 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease. csanz.edu.au (accessed 10 Nov 2026).
- Australian Technical Advisory Group on Immunisation. Australian Immunisation Handbook. Canberra: Department of Health, Disability and Ageing. immunisationhandbook.health.gov.au (accessed 10 Nov 2026).
Recommended reading for RACGP fellowship candidates
- Sindone et al., MJA 2022 consensus statement — short, Australian, and the clearest summary of current HFrEF, HFmrEF and HFpEF drug treatment.
- NHFA/CSANZ heart failure guideline 2018 — for diagnosis, disease management programs and non-drug care.
- Therapeutic Guidelines: Cardiovascular and AMH — doses, titration and interactions.
- PBS Schedule — current restrictions for sacubitril/valsartan, SGLT2 inhibitors, ivabradine, tafamidis and mavacamten.
- Austroads, Assessing Fitness to Drive — heart failure, cardiomyopathy and device standards.
- ESC 2023 cardiomyopathy guideline — family screening and the cardiomyopathy classification.
- Murtagh’s General Practice (dyspnoea and heart failure chapters); RACGP check and AJGP heart failure articles; RACGP curriculum: cardiovascular health.
Version history
| Version | Date | Changes |
|---|---|---|
| 2026–27 (v1.0) | 10 Nov 2026 | First edition, with engagement layer, study-priority stars and end-of-lesson flashcards. Based on the 2018 NHFA/CSANZ guideline, the 2022 MJA consensus statement, ESC 2021/2023 heart failure and 2023 cardiomyopathy guidelines, the PBS and Austroads. |
© GP Institute of Australia. For educational use by enrolled candidates only; not for redistribution. This lesson summarises Australian guidelines for exam preparation and does not replace current clinical guidelines or clinical judgement. Always check doses and PBS restrictions in current Therapeutic Guidelines, AMH and the PBS Schedule.